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ABSTRACT
Generalized arterial calcification of infancy (GACI) is an autosomal recessive
disorder caused by mutations in the ENPP1 gene. It is characterized by mineralization
of the arterial blood vessels, often diagnosed prenatally, and associated with death
in early childhood. There is no effective treatment for this devastating disorder. We
previously characterized the Enpp1asj mutant mouse as a model of GACI, and we
have now explored the effect of elevated dietary magnesium (five-fold) in pregnant
mothers and continuing for the first 14 weeks of postnatal life. The mothers were
kept on either control diet or experimental diet supplemented with magnesium.
Upon weaning at 4 weeks of age the pups were placed either on control diet or high
magnesium diet. The degree of mineralization was assessed at 14 weeks of age
by histopathology and a chemical calcium assay in muzzle skin, kidney and aorta.
Mice placed on high magnesium diet showed little, if any, evidence of mineralization
when their corresponding mothers were also placed on diet enriched with magnesium
during pregnancy and nursing. The reduced ectopic mineralization in these mice was
accompanied by increased calcium and magnesium content in the urine, suggesting
that magnesium competes calcium-phosphate binding thereby preventing the mineral
deposition. These results have implications for dietary management of pregnancies in
which the fetus is suspected of having GACI. Moreover, augmenting a diet with high
magnesium may be beneficial for other ectopic mineralization diseases, including
nephrocalcinosis.

INTRODUCTION

death, the relative risk being up to 12.5-fold [1]. Vascular
calcification is a common complication in calciphylaxis, a
highly morbid disorder seen mostly in patients with chronic
kidney disease [3]. There are two forms of pathological
mineralization involving peripheral connective tissues.
Metastatic calcification results from elevated serum levels
of phosphate and/or calcium exceeding the homeostatic
capacity of cells and tissues, in conditions such as chronic
renal failure and hyperparathyroidism. In dystrophic
calcification, serum calcium and/or phosphate levels are
normal, but calcification is a secondary consequence of
trauma to the tissues, for example in autoimmune diseases,
such as systemic lupus erythematosus, scleroderma and
dermatomyositis [4]. Dystrophic calcification is also

Ectopic mineralization, i.e., deposition of calcium
and phosphate complexes in soft connective tissues,
represents a broad class of diseases and a significant
medical problem [1, 2]. These diseases include hardening
of the arteries associated with aging, chronic kidney
disease, osteoarthritis, cancer, diabetes, and autoimmune
diseases. Ectopic mineralization, particularly when
affecting the cardiovascular system, is a major cause
of morbidity and mortality. For example, it has been
demonstrated that coronary artery calcification in a cohort
of 25,253 patients was an independent risk factor to
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frequently noted in diseased tissue, such as chronic
ulcers and granulomas as well as in benign and malignant
neoplasms. Collectively, ectopic mineralization is
a consequence of a number of contributing genetic,
metabolic, and environmental factors which has made
uncovering the precise molecular basis and clinical
management of these disorders exceedingly difficult.
A number of heritable ectopic mineralization
disorders and their corresponding mouse models, as
exemplified by generalized arterial calcification of
infancy (GACI), provide insight into the pathophysiology
of soft tissue mineralization under normal calcium and
phosphate homeostasis [5, 6]. GACI is a rare heritable
disease characterized by prenatal onset of widespread
mineralization of large and medium-sized arteries,
resulting in cardiovascular collapse and death in the
neonatal period [7]. GACI is often diagnosed prenatally
through ultrasound, and the newborns manifest with
severe hypertension, cardiomyopathy and heart failure,
resulting in demise of the affected individuals in most
cases during the first year of life [8]. GACI is caused in
most cases by loss-of-function mutations in the ENPP1
gene, which codes for ectonucleotide pyrophosphatase/
phosphodiesterase 1 (ENPP1), an extracellular
membrane bound glycoprotein that hydrolyzes adenosine
triphosphate into adenosine monophosphate and inorganic
pyrophosphate (PPi) [9, 10]. In the absence of the ENPP1
activity, plasma levels of PPi, a powerful inhibitor of
ectopic mineralization, are significantly reduced, and
therefore, progressive vascular mineralization takes
place. In addition, ENPP1 mutations have been identified
in some patients with pseudoxanthoma elasticum (PXE),
another heritable ectopic mineralization disorder, although
most cases with this disorder harbor mutations in the
ABCC6 gene [6, 11].
There is no effective or specific treatment for
GACI. A few studies have suggested that administration
of bisphosphonates, stable and non-hydrolyzable PPi
analogues, might be helpful in counteracting the ectopic
mineralization and reducing mortality in GACI [8, 12,
13]. However, a potential complication of this approach
is the severe skeletal toxicity associated with prolonged
use of bisphosphonates in patients with GACI [14]. Lack
of consensus about the efficacy of these compounds and
limited available data make it difficult to determine if
bisphosphonates offer a safe and effective treatment for
GACI.
A number of mouse models, both spontaneous
and genetically engineered, have been described to
recapitulate the clinical features of human GACI due
to genetic alterations in the ENPP1 gene. One of them,
the Enpp1asj mouse (hereafter referred to as asj), was
recently identified as a result of ENU treatment in The
Jackson Laboratory Neuromutagenesis Program [15].
Pathological examination of these mice revealed a stiff
posture, unbendable joints in the front legs with severe
www.impactjournals.com/oncotarget

osteoarthritis and mineralization, and consequently, this
mutant mouse was designated as ‘‘ages with stiffened
joints (asj)’’. These mice harbor a homozygous missense
mutation in the Enpp1 gene (p.V246D) that results in
markedly reduced ENPP1 enzymatic activity and lowered
plasma PPi concentration that subsequently allows for
ectopic mineralization of soft connective tissues in the
skin and arterial blood vessels to ensue [15]. Previous
studies in Abcc6-/- mouse model of PXE revealed that an
increase in dietary magnesium by five-fold over that in
control diet completely abolished ectopic mineralization
in the skin [16, 17]. In this study, we investigated the
effects of dietary magnesium supplementation on ectopic
mineralization in the skin and vascular tissues in asj mice,
a model for GACI which shares genotypic and phenotypic
overlap with PXE. Our results suggest that dietary
magnesium supplementation, if administered during
pregnancy and continue to postnatal period, may provide
an effective way to counteract ectopic mineralization that
causes considerable mortality in GACI.

RESULTS
High magnesium content in the diet prevents
ectopic mineralization in the offspring
In this study, we tested the hypothesis that diet
augmented with magnesium might counteract the ectopic
mineralization in the skin and vascular tissues, using asj
mice as a preclinical platform. Pregnant mothers were
placed on either control diet or magnesium enriched
diet during the entire pregnancy and the subsequent
postpartum period. Wild type and asj mice at 4 weeks
of age at weaning were placed on specific diets, either
control diet or high magnesium diet for additional 10
weeks, as indicated in Table 1. At the age of 14 weeks,
tissue mineralization was determined in the asj offspring.
We have previously demonstrated that the asj mice
on control diet develop stiffening of the joints, particularly
the forepaws, which resulted in a slow, hobbling gait that
worsened as they aged (Figure 1, group B), a finding
that was not present wild type mice (Figure 1, group A)
[15]. Among all groups that were tested, the asj mice fed
high magnesium diet whose mothers were also fed high
magnesium diet (Figure 1, group E) showed less stiffened
phenotype of their forepaws when examined at 14 weeks
of age. The mice were sacrificed, and muzzle skin, kidneys
and aorta were harvested for mineralization analysis.
The effect of diet enriched with magnesium on
ectopic mineralization was assessed by two independent
examinations. The left side muzzle skin, left kidney and
descending thoracic aorta were collected and processed
for semi-quantitative histopathological examinations.
The degree of mineralization in right side muzzle skin,
38153
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Table 1: Experimental groups of Enpp1asj mice by genotype and treatment1)
Group Genotype of pups Diet pregnant mothers placed on Diet pups placed on
A
WT
control
control
B
asj
control
control
C
asj
control
High Mg
D
asj
High Mg
control
E
asj
High Mg
High Mg

No. of pups examined (M+F)
9 (6+3)
10 (5+5)
11 (6+5)
13 (6+7)
12 (6+6)

The pregnant mothers were placed on either control diet or magnesium-supplemented diet (high Mg diet) during pregnancy
and nursing. The pups, at 4 weeks of weaning, were assigned to either control diet or high Mg diet for additional 10 weeks.
The mice were sacrificed at the age of 14 weeks for mineralization analysis. WT, wild type; M, male; F, female.
1)

right kidney and abdominal aorta was quantified by a
direct chemical assay of calcium content in solubilized
tissues. Specifically, Alizarin red stains in wild type mice
did not show any signs of mineralization (group A, data
not shown), while extensive mineralization was noted
in the dermal sheath of vibrissae in muzzle skin, kidney
and aorta in asj mice on control diet whose mothers were
also placed on control diet (Figure 2, group B). Elevated
magnesium content in the maternal diet (five-fold) resulted
in significantly reduced mineralization in asj offspring
who were also placed on high magnesium diet (Figure 2,
group E). The difference in tissue mineralization was also
demonstrated by quantitative assay of calcium content in
these tissues. High magnesium content in the diet of asj
pups post weaning (Figure 3, group C) or in the maternal
diet alone (Figure 3, group D) did not appreciably change
the degree of mineralization in muzzle skin and aorta,
as compared to the corresponding mice fed control diet
(Figure 3, group B). In contrast, the asj mice fed a high
magnesium diet with mothers on the same diet (Figure 3,

group E) showed significantly reduced amount of calcium
in muzzle skin, kidney and aorta, and quantitatively the
calcium values were at the same low level as noted in wild
type mice (Figure 3, group A). In addition, the asj mice
fed a high magnesium diet whose mothers were on control
diet also showed markedly reduced calcium content in the
kidney (Figure 3, group C). Collectively, histopathologic
analyses and quantitative calcium determinations
demonstrated that elevated magnesium content (five-fold)
in the diet prevents ectopic mineralization in asj offspring
with mutations in the Enpp1 gene.
The magnesium content in the tissues was also
assessed in asj mice as a result of feeding on magnesiumsupplemented diet. The tissues from asj mice on control
diet (group B) and high magnesium diet (group E)
were analyzed at 14 weeks of age. First, the elemental
composition in muzzle skin sections was analyzed
by energy dispersive X-ray of the mineralized areas
in the vibrissae. The analysis revealed calcium and
phosphorus as the principal ions in the tissues (Figure 4).

Figure 1: Magnesium treatment improves the stiffened joints phenotype in asj mice at 14 weeks of age. The asj mice on

control diet (group B) develop stiffening of the joints leading to contractures as shown on the front paws (arrows) in comparison with a
corresponding wild type mouse (group A). The asj mice on high magnesium diet whose mothers were also placed on the same diet during
pregnancy and nursing had improved phenotype of stiffening of the joints in the front paws (group E).
www.impactjournals.com/oncotarget
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Table 2: Calcium, phosphorus, and magnesium concentrations in the serum and urine of mice1)
Group
A
B
C
D
E

Serum concentration
Calcium
Phosphorus
(mg/dL)
(mg/dL)
10.8 ± 0.2
6.5 ± 0.4
10.6 ± 0.1
6.7 ± 0.6
10.3 ± 0.4
5.2 ± 0.6
10.9 ± 0.2
6.2 ± 0.3
10.9 ± 0.1
7.2 ± 0.4

Magnesium
(mg/dL)
3.5 ± 0.1
4.3 ± 0.4
4.8 ± 0.3
4.1 ± 0.2
4.5 ± 0.1

Urine concentration
Calcium
Phosphorus
(mg/dL)
(mg/dL)
3.4 ± 0.7
89.9 ± 18.0
4.1 ± 0.6
116.1 ± 13.0
99.7 ± 16.6**
16.4 ± 3.2**
4.5 ± 0.5
141.1 ± 14.4
103.7 ± 18.4**
9.0 ± 1.4**

Magnesium
(mg/dL)
43.9 ± 3.4
51.9 ± 2.3
61.6 ± 0.3**
46.0 ± 1.9
61.5 ± 0.2**

Data are expressed as means ± SE; n = 8-13 mice per group. ** P < 0.01, as compared with asj mice on control diet in group
B. For description of different groups, see Table 1.
1)

High magnesium content in the diet alters serum
and urinary mineral profiles

Topographic mapping revealed that these ions co-localize
in the mineralized connective tissue capsule, suggesting
the presence of hydroxyapatite. Magnesium does not
constitute for the major element in the tissues, and in
fact, as compared to calcium and phosphorus, magnesium
signal is extremely low (Figure 4). Second, the amount
of magnesium was quantitatively measured in solubilized
muzzle skin, kidney and abdominal aorta samples. The
amount of magnesium (µmol Mg/gram tissue) was not
statistically different: 22.6 ± 0.9 and 21.6 ± 2.4 for muzzle
skin, 15.3 ± 1.1 and 16.2 ± 1.3 for kidney, and 7.8 ± 0.4
and 7.6 ± 0.4 for abdominal aorta, from asj mice in groups
B and E, respectively (mean ± SE).

To examine the metabolic consequences of the
experimental diets, the serum and urine concentrations
of calcium, phosphorus and magnesium were determined
in mice at the end of the 14-week experimental diet.
No significant differences were noted in the serum
concentrations of these components (Table 2). In contrast,
significant changes were noted in calcium, phosphorus,
and magnesium concentrations in the urine of mice
after feeding with magnesium. Specifically, over 24-fold
increase in calcium concentration and > 85% reduction
in the phosphorus concentration were noted in asj mice

Figure 2: Magnesium treatment prevents ectopic soft tissue mineralization in asj mice as revealed by histopathology.

The asj mice and their respective mothers placed on control diet develop ectopic mineralization of the dermal sheath of vibrissae in muzzle
skin, kidney and aorta, when examined at 14 weeks of age by histopathology with Alizarin red stain (group B). Markedly reduced mineral
deposition was noted in asj mice fed high magnesium diet when their respective mothers were also placed on high magnesium diet during
pregnancy and nursing (group E). Scale bar = 0.4 mm.
www.impactjournals.com/oncotarget
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Table 3: Measurements of serum PTH and urinary albumin1)
Group
Serum PTH (pg/mL)
Urine albumin (g/dL)
A
56.8 ± 8.7
< 0.01
B
44.2 ± 7.6
< 0.01
C
47.0 ± 13.3
< 0.01
D
61.6 ± 9.3
< 0.01
E
38.9 ± 4.7
< 0.01
Data are expressed as means ± SE; n = 8-13 mice per group. No statistical differences are noted as compred to the asj mice
on control diet in group B. PTH, parathyroid hormone. The urinary albumin levels are below the detection limit of 0.01 g/dL.
For description of different groups, see Table 1.
1)

High magnesium content in the diet does not
cause hormonal and metabolic alterations

fed high magnesium diet (Table 2, groups C and E). In
addition, the concentration of urinary magnesium was
significantly increased in asj mice fed high magnesium
diet (Table 2, groups C and E). Feeding mice with
elevated magnesium content resulted in more calcium
and magnesium excreted into urine, suggesting direct
interactions by which magnesium and calcium ions
compete in phosphorus binding leading to more soluble
magnesium phosphate complexes.

As inhibition of ectopic mineralization by
magnesium could involve changes in the parathyroid
hormone (PTH) action [18], we also measured the serum
concentrations of PTH by an ELISA assay in mice fed
control diet or diet enriched in magnesium at the end of
the experimental diet. Although individual variability in
PTH values was noted, the average concentrations were
not statistically different in different groups (Table 3).

Figure 3: Magnesium treatment reduces ectopic soft tissue mineralization in asj mice as determined by the direct
chemical assay of calcium. Muzzle skin biopsies, kidney and aorta were harvested and calcium content was quantitated by a chemical

assay. Note the significantly elevated calcium content in asj mice (group B) as compared with the wild type mice (group A) on the control
diet. Treatment of asj mice with diet supplemented with magnesium whose pregnant mothers were also kept on the same diet (group E)
resulted in a significant reduction in the calcium content in these tissues in comparison with the asj mice on control diet (group B). Feeding
asj mice with magnesium after weaning whose mothers were fed control diet (group C) also significantly reduced the calcium content of
the kidney as compared with asj mice on control diet (group B). Mean ± SE; n = 9-13 mice per group. * P < 0.05, ** P < 0.01, vs group A;
+
P < 0.05, ++ P < 0.01, vs group B.
www.impactjournals.com/oncotarget
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To determine whether feeding with magnesium
affects renal function, we measured urinary albumin
concentrations as an indicator of renal function. In all mice
analyzed, albumin levels in the urine samples were below
the detection limit of 0.01 g/dL (Table 3), suggesting
normal renal function in mice fed with magnesium for up
to 14 weeks of time.

when administered subcutaneously in asj mice with
reduced ENPP1 enzymatic activity, prevents mortality and
vascular mineralization [22].
There are several lines of evidence suggesting that
diet, particularly with respect to its magnesium content,
may modify the severity of ectopic mineralization. Early
studies using transgenic mice with targeted ablation of
the Abcc6 gene as a model for PXE have demonstrated
that increased levels of magnesium in the diet, five times
over the standard rodent diet, completely abolished the
ectopic mineralization in these mice [16, 17]. At the same
time, addition of phosphate, two times over the standard
diet, when combined with reduced (20%) magnesium
content, significantly accelerated the mineralization in
mouse models for PXE and GACI; this diet has been
designated as the “acceleration diet” [15, 23, 24]. In
addition, maternal “acceleration diet” during pregnancy
can influence the degree of ectopic mineralization in the
offspring [25].
The results of our study clearly demonstrate that
magnesium, when added to the mouse diet in amounts
that increase the magnesium concentration by five-fold,
is able to prevent the ectopic mineralization in skin and
vascular tissues in asj mice when the mothers are also
placed on the same diet during pregnancy. When only the
asj mice were kept on high magnesium diet post-weaning,
or only the mothers were placed on high magnesium diet
while pups were maintained on control diet, the efficacy
of magnesium on preventing mineralization is reduced.
Supplementation of magnesium in the mouse diet did not
change serum calcium, phosphorus, and magnesium levels,
while increased calcium and magnesium concentrations
were found in the urine. No overt side effects were noted
in the mice fed with five-fold increase of magnesium
content in mouse diet.

DISCUSSION
Diseases of ectopic mineralization of connective
tissues range from rare heritable diseases, such as GACI,
to common maladies in the ageing population, such as
arteriosclerosis. The characteristic feature of GACI is
profound arterial mineralization often diagnosed by
prenatal ultrasound during pregnancy. The affected
children are born with cardiovascular complications with
older reports indicating ~85% mortality rate at 6 months
of age [19]. Current medical strategies preventing or
reversing the connective tissue mineralization present in
GACI are ineffective and novel experimental therapeutics
are clearly needed. One study reported that intensive
treatment with bisphosphonates lowered mortality of
GACI to 55% at 6 months [8], while other studies showed
very little, if any, effect [20]. Bisphosphonates have
also been reported to be accompanied by severe side
effects, particularly on the development of bones [14].
The potential efficacy of bisphosphonates has been also
explored in asj mutant mouse as a preclinical platform
for GACI. The results demonstrated that bisphosphonate
treatment may be beneficial by a dual effect for preventing
ectopic soft tissue mineralization while correcting
decreased bone mineralization in asj mice [21]. Recently,
it was shown that recombinant ENPP1-Fc fusion enzyme,

Figure 4: Energy dispersive X-ray analysis demonstrates hydroxyapatite in the muzzle skin biopsies containing
mineral deposits in the dermal sheath of vibrissae. Elemental composition analysis reveals the presence of calcium (Ca) and
phosphorus (P) as the principal ions in the muzzle skin of asj mice in groups B and E. There is very little magnesium (Mg) present in the
tissues. The presence of carbon (C) reflects the carbon carrier that holds the samples. X-ray topography of the distribution maps of calcium
(green) and phosphorus (red) reveals co-localization in the areas of ectopic mineralization. Scale bar = 0.2 mm.
www.impactjournals.com/oncotarget
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The mechanisms for the inhibition of ectopic
mineralization by magnesium could be systemic
interfering with the calcium metabolism mediated through
the PTH synthesis and/or secretion. In support of this
suggestion are observations that magnesium deficiency is
associated with insufficient PTH action and can lead to
reduced responses to calcitropic hormones [18]. However,
determination of serum PTH levels in the treated asj
mice did not reveal significant differences. An alternate
mechanism may involve direct interactions between
magnesium and calcium ions in the mineralization process,
i.e., magnesium competes calcium-phosphate binding and
forms magnesium phosphate complexes which are soluble,
thereby preventing the mineral deposition of calcium
phosphate complexes. The elevated urinary calcium and
magnesium results favor the latter hypothesis.
Our observations have implications for the clinical
management of patients with GACI caused by ENPP1
mutations. Specifically, the results of our study suggest
that dietary magnesium might be helpful for treatment
of patients with GACI. Identification of mutations in
the ENPP1 gene can be used for confirmation of the
clinical diagnosis, carrier detection and presymptomatic
identification of affected individuals with family history
of GACI. Prenatal genetic testing from chorionic villus
sampling or from fetal cells in maternal circulation is also
possible for families with affected individuals. For patients
with family history, as soon as the clinical diagnosis and
mutation analysis have been made during pregnancy,
elevated magnesium in maternal diet might slow down the
progression of GACI in the fetus and improve the quality
of postnatal life of patients with this, currently intractable,
disease. The results from the preclinical mouse model
of GACI suggest that magnesium supplementation in
pregnant mothers or the newborn child alone would not be
sufficient, but rather the pregnant mothers would have to
receive treatment followed by continued treatment of the
affected newborn suspected of GACI. It should be noted
that the daily dose of magnesium administered to the mice
was higher than the recommended daily dose for humans
(300-400 mg per day). Thus, the efficacy in humans
should be tested in controlled clinical trials with careful
monitoring of side effects. The similar clinical features and
pathophysiology in GACI and other common conditions
presenting with vascular mineralization suggests that these
disorders may be treated by a common approach—dietary
magnesium treatment.

mice [15]. The wild type and homozygous asj mice were
generated from heterozygous breedings. The mice were
maintained on standard rodent laboratory diet (Laboratory
Autoclavable Rodent Diet 5010; PMI Nutritional
International, Brentwood, MO) under standard conditions.
Mice were divided into five groups (A, B, C, D and E)
based on their Enpp1 genotype and treatment regiments.
Groups A and B were wild type and asj mice, respectively,
fed a control diet for both pregnant mothers and pups until
pups became 14 weeks of age. The pregnant mothers in
group C were fed the control diet during pregnancy and
nursing. At 4 weeks of weaning, the asj pups were placed
on diet with a five-fold increase in magnesium for another
10 weeks. The pregnant mothers in group D were fed the
high magnesium diet during pregnancy and nursing. At 4
weeks of weaning, the asj pups were placed on control diet
for another 10 weeks. The asj mice in group E and their
corresponding mothers received the high magnesium diet
during pregnancy and postnatally. At 14 weeks of age, the
mice were sacrificed for analysis. For different groups, see
Table 1.
All protocols were approved by the Institutional
Animal Care and Use Committee of Thomas Jefferson
University.

Histopathology of soft connective tissues
Biopsies from muzzle skin containing vibrissae
(left side) as well as the internal organs (left kidney and
descending thoracic aorta) were fixed in 10% phosphatebuffered formalin and embedded in paraffin. Paraffin
sections (6 µm) were stained with hematoxylin-eosin
(H&E) and Alizarin red stains using standard methods
[15].

Quantification of calcium and phosphorus
To quantify the calcium content in mouse tissues,
muzzle skin biopsies (right side), right kidney, and
abdominal aorta were harvested and decalcified with in
HCl solution. The solubilized calcium was determined
in the HCl supernatants colorimetrically by the
ơ-cresolphthalein complexone method (Calcium (CPC)
Liquicolor; Stanbio Laboratory, Boerne, TX). The values
for calcium were normalized to tissue weight. Calcium in
the serum and urine samples was quantitatively assayed
as above. The serum and urinary phosphorus content was
determined with a Malachite Green Phosphate Assay kit
(BioAssay Systems, Hayward, CA).

MATERIALS AND METHODS
Mice and diet

Quantification of magnesium

C57BL/6J-Enpp1asj/GrsrJ mice on a C57BL/6J
background were obtained from The Jackson Laboratory
(Bar Harbor, ME); these mice are referred to as the asj

The magnesium concentrations in the mouse serum
and urine were measured using the QuantiChromTM
Magnesium Assay Kit (BioAssay Systems). The
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